Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

272.82
-5.5350-1.99%
Volume:270.50K
Turnover:73.90M
Market Cap:13.02B
PE:-55.89
High:275.88
Open:275.39
Low:272.06
Close:278.35
52wk High:303.31
52wk Low:144.26
Shares:47.74M
Float Shares:47.20M
Volume Ratio:0.44
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8814
EPS(LYR):-2.9122
ROE:-7.52%
ROA:4.11%
PB:4.59
PE(LYR):-93.68

Loading ...

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

GlobeNewswire
·
Jun 09

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Incyte (INCY) and Pfizer (PFE)

TIPRANKS
·
Jun 08

Charles River Laboratories International Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Jun 06

Analysts Are Bullish on Top Healthcare Stocks: Charles River Labs (CRL), TransMedics Group (TMDX)

TIPRANKS
·
Jun 06

RBC Capital Keeps Their Buy Rating on Charles River Labs (CRL)

TIPRANKS
·
Jun 06

Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says

MT Newswires Live
·
Jun 05

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Charles River Labs (CRL) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Jun 04

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

GlobeNewswire
·
Jun 04

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 04

Max Smock Reiterates Buy on Charles River Laboratories, Citing Achievable 2026 Targets and Margin Expansion Upside

TIPRANKS
·
Jun 03

Charles River Laboratories International Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Jun 03

URA announces nine new sites under Confirmed List in 2H2026 GLS programme, including white site at Jurong Lake District

Jovi Ho
·
Jun 03

Charles River Laboratories posts investor presentation on growth strategy, demand trends and 2026 outlook

Reuters
·
Jun 02

FDA Declines Approval for Cingulate's ADHD Treatment Candidate

Deep News
·
Jun 02

Nyse Order Imbalance 67834.0 Shares on Buy Side

THOMSON REUTERS
·
Jun 02

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

GlobeNewswire
·
Jun 01

Charles River Labs to present at William Blair Growth Stock Conference

Reuters
·
Jun 01

Charles River Laboratories International Inc. Stock Advances 10.2%, Outperforms Peers

Dow Jones
·
May 29

Movement Alert|Charles River Laboratories Rises 8.73% in Regular Trading, Trading at $178.9

Market Focus
·
May 29